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of the CytoSorb® adsorber in ICU
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Study protocol and preliminary results
Electronic supplementary material
The online version of this article (https://doi.
org/10.1007/s00063-017-0342-5) includes
(1) ﬂowcharts and data content in the eCRF,
(2) severity scores, (3) criteria deﬁning sepsis
and septic shock, and (4) abbreviations. The
article and the appendix are available at
http://www.springermedizin.de/mk-im. The
appendix can be found at the end of the
article under “Supplementarymaterial”.
Extracorporeal blood puriﬁcation tech-
niques have been used for treating criti-
cally ill patients for more than 15 years.
This approach is based on current ev-
idence that an excessive inﬂammatory
host response which is accompanied by
acontinuous releaseof inﬂammatoryme-
diators may contribute to multiple organ
failureandﬁnallydeath. Cytotoxiceﬀects
with substrate loss in several organs [1]
and immune paralysis [2] resulting in an
increased susceptibility to secondary in-
fections characterize the consequences of
an uncontrolled release of inﬂammatory
mediators. This led to the view that elim-
inating inﬂammatory mediators, bacte-
rial toxins, and tissue degradation pro-
teins from the systemic circulationmight
restore immunoreactivity and positively
aﬀect outcomes. Several mechanisms of
action are supposed to account for the
eﬃcacy [3–5] and many approaches of
extracorporeal blood puriﬁcation tech-
niques (hemoﬁltration, hemadsorption,
plasmapheresis, etc.) have been inves-
tigated [6]. By recording physiological
parameters and surrogatemarkers, many
studies have shown that these approaches
are eﬃcient and well tolerated. How-
ever, questions surrounding the appro-
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
– Use of CytoSorb®
– Age ≥ 18 years
– Signed informed consent
Exclusion criteria
– None
priate application, timing, duration, and
frequency remain tobe elucidated. In ad-
dition, studies with a higher number of
patients should assess eﬃcacy by record-
ing clinically relevant study endpoints
(mortality, organ dysfunction).
Clinically established methods diﬀer
in several aspects, such as the spectrum
of retainable pathogenic molecules (e. g.,
cytokines and/or endotoxins), loss and
need for supplementation of physiolog-
ical blood components (low molecular
substances, albumin, antibiotics), use-re-
lated technical and staﬀ eﬀort, and prod-
uct costs.
Severalmedical devices that are based
on the principle of hemadsorptionmeth-
ods are in diﬀerent phases of clinical de-
velopment [7]. The active component of
the approved Toraymyxin (Toray Indus-
tries, Japan) is polymyxin B, an antibi-
otic that is immobilized on polystyrene
ﬁbers. The active ingredient enables
the extraction of endotoxins. Its use
is associated with high costs. Another
product, which adsorbs the endotoxin
LPS (AltecoMedical, Sweden), has failed
to show convincing results in clinical
testing. The product OXiris (Gambro-
Hospal, France) is being clinically tested.
It contains a biopolymer that is able to
eliminate endotoxins and cytokines. The
MATISSE system (Fresenius, Germany)
relies on the adsorption qualities of hu-
man albumin which is immobilized on
polystyrene. However, clinical results
remain unconvincing. The nonspeciﬁc
adsorption of cytokines (but not en-
dotoxins) on a synthetic resin module
with subsequent hemoﬁltration is used
in the product of the Italian manufac-
turer Bellco. Eﬃcacy in septic patients
is currently being tested.
The approved product CytoSorb®
(CytoSorbents, USA) contains a bio-
compatible polystyrene and divinylben-
Table 2 Flow chart for study visits and data assessment in patients with sepsis
Activity Base-
line
Exam
1
Treat-
ment
Exam
2
Follow
-up
Inclusion criteria x – – – –
Indication x – – – –
Demographics and type of admission x – – – –
Comorbidities for APACHE II/SAPS II x – – – –
Sepsis criteria x – – – –
Site and source of infection x – – – –
Physiological parameters for APACHE II/SAPS II – x – – –
Physiological parameters for the SOFA score – x – x –
Relevant diagnostic tests – x – x –
Treatments with CytoSorb® (duration, antico-
agulation, blood pump speed, vasopressors,
hydrocortisone)
– – x – –
Renal replacement therapy (type, ﬁlter) – x x x –
Complications – – – x –
Length of stay on ICU and in hospital – – – – x
ICU and hospital survival status – – – – x
Days with mechanical ventilation – – – – x
Days with renal replacement therapy – – – – x
Days on vasopressors – – – – x
Assessment of treatment eﬀect – – – – x
Exam 1 = Time period of up to 24 h before CytoSorb® use; Exam 2 = Time period of 24 h after end
of CytoSorb® use; Follow-up = Discharge from hospital
zene copolymer as a sorbent. The agent
eliminates inﬂammatory cytokines and
metabolic products in a quick and reli-
able way, but cannot adsorb endotoxins.
Its eﬃcient and safe use in patients with
septic shock was proven in a random-
ized clinical multicenter study (NCT
00359130).
Another study that recently started
investigates the adsorber’s use in elec-
tive cardiopulmonary surgical interven-
tions. As the product is compatible with
other methods of extracorporeal blood
puriﬁcation (renal replacement therapy,
cardiopulmonary bypass), an above-av-
erage usage in clinical practice is very
likely, and the medical community has
signaled signiﬁcant interest [8].
Objectives and design
The aim of this registry is to record the
use of CytoSorb® under real-life condi-
tions in as many cases as possible. All
CytoSorb® applications in diﬀerent clin-
ical settings and in all patients who are
treated with this technology are expected
to be documented. The objectives of the
registry are collection of real-life data
on a broad scale, centralized, structured
and comprehensive documentation, and
controlled data exchange. The informa-
tion gatheredwill be used to augment the
knowledge on the clinical eﬃcacy of the
technology, to optimize the quality of its
therapeutic application, and to identify
and promptly handle possible complica-
tions related to the use ofCytoSorb®. The
registry will record relevant information
in the course of product use, e. g., diag-
nosis, comorbidities, course of the con-
dition, treatment, concomitant medica-
tion, and clinical laboratory parameters.
An active form of data collection where
data is prospectively collected by qual-
iﬁed staﬀ is particularly suited for this
purpose [9]. Registry data might help
close knowledge gaps and open practical
issues. Due to the patient group’s het-
erogeneity, the registry can identify sub-
groups, assess their risk–beneﬁt proﬁle
and examine their safety proﬁle. Registry
data are essential for assessing a therapy’s
signiﬁcance within the healthcare land-
scape [10]. Institutions that contribute
data totheregistrybeneﬁt inseveralways:
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preliminary results
Abstract
Introduction. The aim of this clinical registry
is to record the use of CytoSorb® adsorber
device in critically ill patients under real-life
conditions.
Methods. The registry records all relevant
information in the course of product use, e. g.,
diagnosis, comorbidities, course of the con-
dition, treatment, concomitantmedication,
clinical laboratory parameters, and outcome
(ClinicalTrials.gov Identiﬁer: NCT02312024).
Primary endpoint is in-hospital mortality as
compared to the mortality predicted by the
APACHE II and SAPS II score, respectively.
Results. As of January 30, 2017, 130 centers
from 22 countries were participating. Data
available from the start of the registry on
May 18, 2015 to November 24, 2016 (122
centers; 22 countries) were analyzed, of whom
20 centers from four countries provided
data for a total of 198 patients (mean age
60.3 ± 15.1 years, 135 men [68.2%]). In all,
192 (97.0%) had 1 to 5 Cytosorb® adsorber
applications. Sepsis was the most common
indication for CytoSorb® treatment (135
patients). Mean APACHE II score in this group
was 33.1 ± 8.4 [range 15–52] with a predicted
risk of death of 78%, whereas the observed
mortality was 65%. There were no signiﬁcant
decreases in the SOFA scores after treatment
(17.2 ± 4.8 [3–24]). However interleukin-6
levels were markedly reduced after treatment
(median 5000 pg/ml before and 289 pg/ml
after treatment, respectively).
Conclusions. This third interim report
demonstrates the feasibility of the registry
with excellent data quality and completeness
from 20 study centers. The results must be
interpreted with caution, since the numbers
are still small; however the disease severity is
remarkably high and suggests that adsorber
treatment might be used as an ultimate
treatment in life-threatening situations. There
were no device-associated side eﬀects.
Keywords
Cytokines · Extracorporeal life support ·
Inﬂammation · Sepsis · Intensive care units
Internationales Register zur Nutzung des Adsorbers CytoSorb® bei Intensivpatienten.
Studienprotokoll und erste Ergebnisse
Zusammenfassung
Einleitung. Zweck des vorgestellten klinischen
Registers ist es, die Nutzung des Adsorbers
CytoSorb® bei kritisch kranken Patienten
unter Realbedingungen zu erfassen.
Methoden. Dokumentiert werden Diagnose,
Komorbiditäten, Verlauf der Erkrankung,
Behandlung, Begleitmedikation und
Laborparameter (ClinicalTrials.gov-Identiﬁer:
NCT02312024). Primärer Endpunkt ist die
Krankenhausmortalität im Vergleich zur
Mortalität, die mit dem APACHE-II- bzw. SAPS-
II-Score prognostiziert wurde.
Ergebnisse. Mit Stand vom 30. Januar 2017
nahmen 130 Zentren aus 22 Ländern am
Register teil. Verfügbare Daten vom 18. Mai
2015 bis 24. November 2016 (122 Zentren;
22 Länder) wurden analysiert. Zwanzig
dieser Zentren aus 4 Ländern lieferten Daten
zu insgesamt 198 Patienten (Alter 60,3 ±
15,1 Jahre, 135 Männer [68,2 %]). Insgesamt
192 (97,0 %) hatten 1–5 Cytosorb®-Adsorber-
Anwendungen. Sepsis war die häuﬁgste
Indikation zur CytoSorb®-Behandlung
(135 Patienten). Der durchschnittliche
APACHE-II-Score in dieser Gruppe betrug
33,1 ± 8,4 mit einem prognostizierten Ster-
berisiko von 78%, während die beobachtete
Mortalität bei 65% lag. Es fanden sich keine
signiﬁkanten Verringerungen in den SOFA-
Scores nach Behandlung (17,2 ± 4,8 [3–24]).
Die Interleukin-6-Spiegel waren allerdings
nach Behandlung deutlich reduziert (im
Median 5000 pg/ml vor und 289 pg/ml nach
Behandlung).
Schlussfolgerungen. Dieser dritte Zwi-
schenbericht belegt die Machbarkeit des
Registers mit einer exzellenten Datenqualität
und -vollständigkeit aus 20 Studienzentren.
Die Ergebnisse sind mit Zurückhaltung zu
interpretieren, da die Patientenzahl immer
noch gering ist; die Erkrankungsschwere
ist allerdings bemerkenswert hoch, was
vermuten lässt, dass der Adsorber als Ultima
Ratio genutzt wird. Es gab keine device-
assoziierten Nebenwirkungen.
Schlüsselwörter
Zytokine · Extrakorporale lebenserhaltende
Maßnahmen · Entzündung · Sepsis ·
Intensivstationen
they will obtain continuous retrospective
feedback of their own results, their data
will be periodically compared with data
from other participating sites, and they
will have access to regularly published
analyses of the results. On the basis of
these data, they can optimize their use
of CytoSorb® [11].
Study population
Allmedical institutionsthatuseCytoSorb®
are eligible for participation. At incep-
tion, data collection was planned for
a period of 3 years. An extension of the
registry duration beyond that period is
possible. The expected sample is around
1000 patients/year. Inclusion criteria
are depicted in . Table 1. There are no
exclusion criteria.
Patients with sepsis and septic
shock
Patients with sepsis/septic shock are en-
rolled according to the afore mentioned
criteria (“Criteria defining sepsis and
septic shock” in Supplementary mate-
rial).
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1
• Site registration on website www.cytosorb-registry.org
2
• Start package sent by ZKS (cooperation contract, ethics 
committee votes)
3
• Site ready for data collection
4
• Patient recruitment by site
5
• Data collection by site
Fig. 19 Require-
ments before data
collection by site
Patients undergoing cardiac
surgery with CPB
This population includes patients who
undergo cardiac surgery with the use
of cardiopulmonary bypass (CPB). The
most frequent cardiac interventions as-
sociated with CPB use include coronary
artery bypass surgery, heart valves re-
placement surgery, and surgery of the
major vessels.
Two possible variants for using the
CytoSorb® device are envisaged, (1) pre-
emptive use aiming to reduce circulating
inﬂammatory cytokines immediately be-
fore and during surgery in risk patients;
(2) postoperative use during the stay in
ICU.
Other patients
Other patients are anyother patients who
are treatedwith theCytoSorb® device and
who are not included in the sepsis/septic
shock or cardiac surgery groups. The
shortlist of indications includes, but is
not restricted to: liver failure, acute pan-
creatitis, severe trauma, extensive burns,
acute respiratory failure.
Data documentation
Data is recorded by assigned staﬀ from
theparticipating centers. If possible, data
from each patient are recorded until be-
ing discharged from hospital. Data col-
lection takes place at four time points
during the hospital stay, as follows:
4 Baseline, i. e. at inclusion
4 Treatment phase with 2 ex-
ams—before and after CytoSorb®
use
4 Final assessment/follow-up at dis-
charge from hospital
Data of patients subject to more than
one CytoSorb® application for diﬀerent
indications are recorded separately; how-
ever, the fact they belong to the same
individual is documented accordingly.
The ﬂow chart for study visits and data
assessment in patients with sepsis, car-
diac surgery, and other indications are
depicted in . Table 2 and “Flowcharts
and data content in the eCRF” in Sup-
plementarymaterial, respectively.
Data management
Data capture takes place via a web ap-
plication on the servers of the Center
for Clinical Studies at Jena University
Hospital with OpenClinica®, a study
management software. OpenClinica
meets all regulatory requirements (GCP,
21CFRPart11). It has an integrated au-
dit trail that records any kind of data
changes automatically. This data record-
ing cannot be modiﬁed by the users. In
order to ensure a pseudonymized analy-
sis of data, each patient data set is given
a unique patient identiﬁcation num-
ber when being entered into the study
database. Data management is done by
using the study management software
OpenClinica®. Prior to its application,
the study database is checked for er-
rors (and corrected if necessary) by the
database programmer and staﬀ involved
(e. g., biometricians, study investigator,
study nurse). Only then is the database
declared ready for use. Data is recorded
in the study database via an encrypted
data link (HTTPS) by use of data entry
masks. While being entered, the data is
already being checked for completeness
and correctness. Missing or obviously
erroneous values produce immediate er-
ror messages that require changes from
the data inputting person. Correctness
of data is veriﬁed by further range, va-
lidity, and consistency checks. The data
collecting centers are contacted if data is
not plausible or missing (query manage-
ment) so that corrections/completions
can be made. Any modiﬁcation of the
data—e. g. because of incorporation of
query answers—is documented in the
database by an audit trail. By applying
a hierarchical, role-based access control,
unauthorized access to patient data is
impossible. Staﬀ is informed about their
obligation of nondisclosure of access
codes. There is a daily backup of all data.
Each center has to complete a hospi-
tal/ICU questionnaire, and for each pa-
tient a questionnaire has to be ﬁlled in.
Recording adverse eﬀects
The CytoSorb® registry is noninterven-
tional observational data collection. Ad-
vice on treatment is not provided by the
registry. Obligations tonotify theauthor-
ities about adverse eﬀects in clinical stud-
ies do not apply. There is no systematic
recordingofadverseeﬀects intheregistry.
However, one objective of the registry is
to record complications or eﬀects that oc-
curred while using CytoSorb®. Compli-
cations have to be recorded in the eCRF.
Implementation of the project
Potential participating centers are ap-
proached by the steering committee and
via information that is delivered together
with the CytoSorb® adsorber. In cases
where a hospital is interested in par-
ticipation, a questionnaire on the hos-
pital’s characteristics needs to be com-
pleted (. Fig. 1). After receipt of this
information, an account in the registry
is created. A contract regulating rights
and obligations is mandatory. Data col-
lecting staﬀ of participating centers is
trained by the responsible CytoSorbReg-
istry project manager at the Center for
Clinical Studies in Jena. The physicians
in charge of the registry are responsible
for on-site dissemination of knowledge
in their centers.
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Table 3 Primary and secondary end-
points
Primary endpoint
Diﬀerence betweenmortality predicted
by scoring systems (APACHE II/SAPS II, Eu-
roSCORE II) and actual mortality within
30 days after intervention
Secondary endpoints
Organ dysfunction (SOFA score diﬀerence)
Concentration of biomarkers IL-6, CRP, PCT,
myoglobin, free hemoglobin
Length of hospital and ICU stay (days)
Duration of mechanical ventilation (days)
Duration of renal replacement therapy
(days)
Duration of vasopressor therapy (days)
ICU intensive care unit, IL-6 Interleukin-6,
CRP C-reactive protein, PCT Procalcitonin,
SOFA Sequential Organ Dysfunction Score
Data analysis
Theprimaryendpoint isobserved in-hos-
pitalmortality, compared to themortality
predicted by the APACHE II and SAPS
II scores, respectively [12, 13]. Survival
rates are compared by use of a logistic re-
gression model according to Knaus et al.
[12]. Signiﬁcance level is preset at α =
0.05. If a diﬀerence is veriﬁable, a binom-
inal test will be performed for the score
groups 0–4, 5–9, 10–14, 15–19, 20–24,
25–29, 30–34, and ≥35. The signiﬁcance
level for the binominal tests will be ad-
justed by use of the Bonferroni–Holm
correction in a mode that a total level of
α = 0.05 is preserved. Major secondary
endpoint is the changeof the SOFAscores
(ΔSOFA). For this, the diﬀerence be-
tween SOFA scores of Exam 1 (within
24 h before CytoSorb® use) and Exam 2
(24 h after CytoSorb® use) are calculated.
ΔSOFA is analyzed by using T-test. Fur-
ther secondary endpoints are depicted in
. Table 3. In addition, an aggregated de-
scription of treatment-related complica-
tions (frequency per organ/system) and
an assessment of the treatment success
(descriptive, frequency analysis) are used
for assessing the safety of CytoSorb® use.
In patients with preemptive CytoSorb®
application the survival analysis will be
performed using the EURO score [14].
Calculation of sample size: the fea-
sibility analysis indicated an expected
number of 1000 patients per year. Based
Table 4 Baseline characteristics of patients according to indications for CytoSorb treatment
Parameter Sepsis/septic
shock
Cardiac surgery
– preemptive
Cardiac surgery
– postoperative
Other indica-
tions
Mean ±
Std
[Range]
N
(135)
Mean ±
Std
[Range]
N (8) Mean ±
Std
[Range]
N
(17)
Mean ±
Std
[Range]
N
(38)
Age [years] 61.5 ±
14.1
[22–92]
135 58.6 ±
13.6
[37–77]
8 67.2 ±
12.2
[44–84]
17 53.2 ±
17.8
[21–84]
38
APACHE II:
score
33.1 ± 8.4
[15–52]
107 n.a. – 22.1 ±
7.3
[2–33]
16 25.5 ±
8.9
[9–51]
26
APACHE II
predicted
mortality
[%]
77.6% ±
20.7
[23–99]
107 n.a. – 31.4 ±
18.2
[2–72]
16 54.1 ±
29.0
[8–98]
26
SAPS II:
score
74.3 ±
16.8
[29–107]
74 n.a. – 50.1 ±
13.2
[27–75]
14 61.9 ±
17.7
[30–97]
20
SAPS II
predicted
mortality
[%]
81.0 ±
20.3
[10–99]
74 n.a. – 46.3 ±
23.8
[8–89]
14 65.0 ±
28.0
[11–98]
20
SD standard deviation
on these ﬁgures, and depending on the
pivotal mortality probability p1, the fol-
lowing odds ratios (OR) can be antici-
pated (two-sided, α = 0.05, power 90 per
cent): p1 = 0.5 → OR 0.81; p1 = 0.7 →
OR 0.80; p1 = 0.8 → OR 0.77 (GPower
3.1.6, z-tests for logistic regression).
Publication of results/registration
of the data collection
The CytoSorb® registry is registered in
the studyregistriesClinicalTrials.govand
the German Registry for Clinical Stud-
ies Freiburg (DRKS). Use of data from
the CytoSorb® registry by participating
centers and external parties is regulated
by a data use agreement. Reports on the
semiannual analyses and a retrospective
access to their own data will be provided
for all participating centers. Publication
of results generated from registry data
are subject to separatepublicationregula-
tions and are coordinated by the steering
committee.
Ethical principles and patient
safety
The registry represents merely a collec-
tion of data on the use of CytoSorb® in
accordance with the prescribing infor-
mation. Therefore, there are no ethical
objections concerning patients and pa-
tient safety. The decision of the attend-
ing physician is the sole factor which
determines the assignment of a patient
to treatment with CytoSorb®, and the
physician’s participation in the registry
does not inﬂuence his decision. Patient
information about the device is provided
and signing of informed consent is an es-
sential precondition for participation in
the registry. In case patients are unable
to consent because of critical illness, lo-
cal practice for collecting data on these
patients has to be applied. This study
protocol has been submitted to the In-
stitutional Review Board (IRB) of the
Faculty of Medicine at Friedrich Schiller
University, Jena that acts as the IRB in
charge for Germany. All German ethic
committees involved are informed about
the participation of centers in their area
of responsibility and the decision of the
IRB in charge. In centers from outside
Germany, approval of the local ethics
commission in charge is obtained and
all national regulations are adhered to.
Data protection
Data collection takes place in the par-
ticipating centers. All collected medi-
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Fig. 29 Patient
recruitment from
May 18, 2015 to Jan-
uary 17, 2017 (248
patients)
cal data are entered by assigned staﬀ of
the centers into a computer-based on-
line data entry system and immediately
transferred to the documentation center
at ZKS Jena. Informed consent on data
collection and use is obtained prior to
inclusion of the patient or at the earliest
possible time. Due to the seriousness of
the medical condition, it has to be as-
sumed that most patients are unable to
consent. Thus, oral or written informed
consent prior to the data collection can-
not be obtained. In this case, the data col-
lecting institutions have to observe their
locally established way of proceeding for
including patients incapable of giving in-
formed consent. The patient’s consent is
recorded in the patient ﬁle. Patients or
their legal representatives have the right
to withdraw their consent and to inter-
ruptparticipation in the study at any time
and without giving reasons. In this case,
the patient’s data will be deleted.
Data collection occurs upon early
stage pseudonymization of the patients.
Participating centers draw up local pa-
tient identiﬁcation lists and allocate
a unique multidigit number to each
patient. Only pseudonymized patient-
relatedmedical data are transferred from
the participating center to the documen-
tation center; no information that allows
identiﬁcation of patients is revealed to
the documentation center.
For answering queries thatmight arise
while checking the data quality and plau-
sibility, the data collecting center is able
to trace back the pseudonym to the pa-
tient for a given period of time. The
patient identiﬁcation list remains at the
data collecting center and canbe accessed
bya limitedgroupof staﬀmembers (prin-
cipal investigators).
The patient identiﬁcation list has to
be kept locked up for at least 10 years
in the data collecting center. The local
principal investigator is responsible for
this. The sponsor has to authorize the
destruction of the patient identiﬁcation
list.
Owners of the registry data are the
steering committee members. The Cen-
ter for Clinical Studies at Jena University
Hospital is appointed as the documenta-
tioncenter, also in charge ofdata process-
ing. Backup of data is done regularly. The
data storagedevices are stored ina locked,
central room, accessible only by the sys-
tem administrator. Only the following
persons have access to the data: staﬀ of
the ZKS that are directly involved in the
project (statisticians, data manager, IT
coordinator). Analyses are carried out
by statisticians of ZKS Jena.
Publication of the data takes place in
an aggregated form only. Information
about individual patients, ICUs or hos-
pitals will not be published or shared.
All data collecting centers can request
access to the data they contributed. Re-
quests for data submitted by external in-
terested parties are decided on by the
steering committee. Again, disclosure of
data takes place in an aggregated form
only.
Data protection statement
Data entry is done in the data collect-
ing centers. Data processing and analy-
sis takes place at the Center for Clinical
Studies at Jena University Hospital. Reg-
ulations of the data protection acts of all
countries concerned are satisﬁed. Access
tothestudydata is limited toregistrystaﬀ.
These persons are bound to secrecy. Data
are protected from unauthorized access.
Sponsor and funding
For the success of a registry, close coop-
eration between users, product suppliers,
and sponsors is crucial. Of particular im-
portance is also the scientiﬁc editing of
knowledge generated from the registry
and the communication of results to all
stakeholders. Jena University Hospital,
represented by Prof. Dr. F. M. Brunk-
horst, is the scientiﬁc institution that runs
this registry. Thesteeringcommittee sup-
ports the implementation of the registry.
The CytoSorb® registry is funded by Cy-
toSorbents Europe GmbH. The Center
for Clinical Studies at Jena University
Hospital is able to provide all necessary
services in the ﬁeld of data management
and project management.
Results from the 3rd interim
report
As of January 30, 2017, 130 centers from
22 countries were participating in the
registry (. Figs. 2 and 3). Data available
from the start of the registry on May 18,
2015 to November 24, 2016 were ana-
lyzed. Atthis timepoint, 122centersfrom
22 countries participated in the registry,
of which 20 centers from four countries
provided data from a total of 198 patients
(. Fig. 4). Baseline data was available in
191 patients, treatment phase data in 195
patients and follow-up-data in 193 pa-
tients.
Baseline characteristics
One hundred and thirty ﬁve (68.2%) pa-
tients were male. Mean age was 60.3 ±
15.1 (min–max 21–92) years. Patients
with preemptive CytoSorb use in car-
diac surgery and other indications were
slightly younger (58.6 ± 13.6 and 53.2 ±
17.8, respectively) thanpatientswith sep-
sis (61.5 ± 14.1), whereas patients with
postoperative use in cardiac surgerywere
slightly older (67.2 ± 12.2). There were
no relevant diﬀerences between the indi-
cation groups in body weight and body
height. Themajority of patients were ad-
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Fig. 39 Therewere 130
participating study centers
from22countries, as of Jan-
uary 17, 2017
Patients with 
completed visits
n=198
Sepsis / septic shock
n=135 (68.2 %)
Cardiac surgery with 
CPB, preemptive 
CytoSorb use in OR
n=8 (4.0 %)
Cardiac surgery with 
CPB, postoperative 
CytoSorb use in ICU
n=17 (8.6 %)
Other indications*
n=38 (19.2 %)
Fig. 49 Indications for Cy-
toSorb treatment. CPB car-
diopulmonary bypass;OR
operation room; ICU inten-
sive care unit. *other indi-
cationswere: liver failure
(n=11), acute pancreatitis
(n=4), trauma(n=6),ARDS
with ECMO (n=12), others
(n=10)
mitted for nonsurgical emergency rea-
sons (91 [46.0%]), surgical emergency
for 70 (35.4%) and elective surgical for
37 (18.7%) of the patients (. Table 4).
Exposition to treatment
The majority of patients (192 patients,
97.0%) had one to 5 Cytosorb adsor-
ber applications, up to 32 adsorbers have
been used per patient.
Meandurationof treatmentwas55.5±
83.2 h for the sepsis group (N=134), 8.3±
13.8 h for patients with preemptive use in
cardiac surgery (N = 8), 45.3 ± 23.3 h for
patientswith postoperative use in cardiac
surgery (N = 16), and 60.8 ± 49.8 h for
patients with other indications (N = 37).
A single adsorber was used for 22.2 ±
15.3 h; the range of duration for a single
adsorber was 15min to 105 h.
Outcome
Sepsis group
Patients with sepsis were predominantly
medical patients (71/135) and exhibited
an extreme high risk of death when
CytoSorb treatment was initiated (mean
APACHE II score in 107/135 patients:
33.1 ± 8.4 [range 15–52]). This is sub-
stantial higher than in other sepsis trials,
where mean APACHE II scores are usu-
ally between20 and25 (for instance in the
MAXSEP and VISEP trials with 20.2 and
21.6 points and 28-day mortality rates
of 22.9 and 25.4%, respectively). The
predicted risk of death in the CytoSorb
group would be around 78%, whereas
the observed mortality was 65%.
This result in the sepsis group is sup-
ported by the high SAPS II scores (74.3 ±
16.8 [29–107]), with a predicted mortal-
ityofaround81%. ThemeanSOFAscores
were also markedly elevated (17.3 ± 3.99
[6–24]). Substantially lower SOFA scores
were observed in for instance the VISEP
andMAXSEP trials (7.7 [7.3; 8.2]points).
There were no signiﬁcant decreases in
the SOFA scores after treatment (17.2 ±
4.8 [3–24]). However, IL-6 levels were
markedly reduced after treatment (me-
dian 5000 pg/ml before treatment and
289 pg/ml after treatment).
Treating physicians rated the condi-
tion as very much/much improved in
45%, as minimally improved in 18%,
and as unchanged in 29%. Two patients
(1.5%) were rated as much worse or very
much worse.
Cardiac surgery with CPB,
postoperative
Patients postoperatively treated follow-
ing cardiac surgery with CPBhad amean
APACHE II score of 22.1 ± 7.3 [2–33]
(16/17 patients), with a predicted mor-
tality of 31%, and an observed mortality
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Übersichten
Table 5 Outcome parameters
Parameter Sepsis/septic
shock
Cardiac surgery –
preemptive
Cardiac surgery –
postoperative
Other indications
N
(135)
N (8) N
(17)
N
(38)
SOFA: score
T1 Mean ±
Std
[Range]
17.3 ±
3.99
[6–24]
113 10.43 ±
5.47
[6–21]
7 16.88 ±
2.13
[12–21]
16 15.39 ±
4.74
[3–23]
31
T2 Mean ±
Std
[Range]
17.15 ±
4.75
[3–24]
82 12.71 ±
3.4
[9–19]
7 17.4 ±
1.99
[13–20]
15 14.94 ±
5.5
[4–23]
31
CRP [mg/L]
T1 Mean ±
Std
[Range]
166 ±
140
[2–611]
121 72 ± 56
[8–180]
8 70 ± 129
[7–521]
16 136 ± 123
[3–495]
29
T2 Mean ±
Std
[Range]
161 ±
124
[2–626]
86 142 ± 94
[43–332]
7 115 ± 74
[23–290]
15 135 ± 96
[12–368]
28
PCT [ng/mL]
T1 Mean ±
Std
[Range]
40.2 ±
69.3
[0–433]
124 0.1 ± 0.1
[0.0–0.2]
4 24.0 ±
17.1
[1.2–47.3]
12 24.7 ±
40.7
[0.1–179]
22
T2 Mean ±
Std
[Range]
25.1 ±
55.2
[0.4–443]
88 8.6 ± 16.0
[0.2–44.6]
7 22.1 ±
22.4
[1.7–67.3]
11 9.3 ± 15.5
[0.2–65]
22
IL6 [pg/mL]a
T1 Median
[Range]
5000
[20–>107]
69 45 1 651
[88–5000]
14 531
[85–122,500]
16
T2 Median
[Range]
289
[0–5000]
51 124
[41–2232]
7 56
[26–206]
12 97
[0.1–6263]
14
Length of ICU stay [days]
Mean ± Std
[Range]
34.9 ±
32.3
[2–165]
49*** 6.2 ± 2.9
[3–11]
6*** 13.9 ± 4.2
[7–21]
11*** 30.2 ± 24
[4–116]
26***
Number
(%) of
deathsb
88
(65.2%)
135 1 (12.5%) 8 5 (29.4%) 17 12 (31.6%) 38
T1 = maximal values 24 h before CytoSorb treatment; T2 = maximal values 24 h after CytoSorb
treatment, Std standard deviation
aIL6 values measured outside the predefined 1 h interval included
bPatients with unknown outcome at database closure have been counted as (still) alive
of 29%. Treating physicians rated the
condition as very much/much improved
in 53%, as minimally improved in 29%,
and as no change in 12%.
Other indications
Patients treated in other indications had
a mean APACHE II score of 25.5 ± 8.9
[9–51] (26/38 patients) with a predicted
mortality of 54% and an observed mor-
tality of 32%.
Treating physicians rated the condi-
tion as very much/much improved in
58%, as minimally improved in 13%,
as no change in 10%, and as minimally
worse in 3%.
Summary and Interpretation
This third interim report demonstrates
the feasibility of the registry with excel-
lent data quality and completeness from
twenty study centers. The results must
be interpreted with caution, since the
numbers are still small; however disease
severity is remarkably high and suggests
that theadsorber treatmentmightbeused
as an ultimate treatment in life-threaten-
ing situations. The observed mortality
is lower than predicted, but the num-
bers are too small to draw conclusions.
There were no device-associated side ef-
fects. However, the durationof treatment
with a single adsorber was relatively pro-
nounced, and blood ﬂow rate was low,
factors which might be improved in or-
der to increase the clinical eﬃcacy of the
device.
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